Want to see NBP full AI Analyst Report?
Top Page
NovaBridge Biosciences
(NASDAQ:NBP)
Select Model
Select Model
Rating:52Neutral
Price Target:
$2.00
▲(6.95% Upside)
Action:Reiterated
Date:08/20/26
The score is held back primarily by weak financial performance (persistent losses, minimal recent revenue, and ongoing cash burn). This is partly offset by constructive earnings-call developments (clinical/regulatory progress supported by a strong cash position) and moderately improving near-term technical momentum, while valuation remains unattractive due to negative earnings and no dividend support.
Positive Factors
Strong liquidity and debt-free balance sheet
The sizable cash position and absence of debt provide financial flexibility to fund near-term clinical milestones, reduce solvency risk, and support development through important oncology and ophthalmology readouts.
Negative Factors
Persistent losses and minimal revenue
NovaBridge lacks a stable revenue base and remains materially unprofitable. Continued reliance on clinical success before commercialization leaves fundamentals vulnerable to trial delays, setbacks, and prolonged operating losses.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong liquidity and debt-free balance sheet
The sizable cash position and absence of debt provide financial flexibility to fund near-term clinical milestones, reduce solvency risk, and support development through important oncology and ophthalmology readouts.
Read all positive factors
NovaBridge Biosciences (NBP) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$216.92M
Dividend YieldN/A
Average Volume (3M)613.91K
Price to Earnings (P/E)―
Beta (1Y)1.24
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees30
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.60
Shares Outstanding115,381,690
10 Day Avg. Volume302,898
30 Day Avg. Volume613,909
Financial Highlights & Ratios
PEG Ratio0.26
Price to Book (P/B)5.02
Price to Sales (P/S)0.00
P/FCF Ratio-8.04
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$9.00Price Target Upside381.28% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.3
Revenue Forecast (FY)N/A
NovaBridge Biosciences Business Overview & Revenue Model
Company Description
NovaBridge Biosciences, a biotechnology firm, primarily focuses on pioneering immuno-oncology treatments for cancer patients within the United States. Its development pipeline features several significant drug candidates: givastomig, a bispecific ...
NovaBridge Biosciences Earnings Call Summary
Earnings Call Date:Aug 20, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Mar 31, 2027
Earnings Call Sentiment Positive
The call communicated strong clinical and regulatory progress—most notably for givastomig (Fast Track designation, FDA Type B guidance, robust Phase Ib signals) and positive topline VIS-101 Phase IIa results—backed by a solid cash position and a debt-free balance sheet with runway through a 2028 Phase III interim readout. However, key execution risks remain: Phase III initiation is contingent on additional financing, the CLDN18.2 competitive landscape is intensifying, PD-L1 negative population strategy is unresolved, and the Visara ophthalmology path will likely require significant capital (and may dilute shareholders). Overall, the positives (clear clinical momentum, regulatory endorsements, and a healthy balance sheet) outweigh the operational and financing uncertainties, yielding cautious optimism but with notable execution risks.Positive Updates
Strong liquidity and debt-free balance sheet
As of June 30, 2026, NovaBridge reported approximately $216 million in cash and investments (about $191 million in cash and cash equivalents and $25 million in equity investments at fair value) and a debt-free balance sheet, with management stating this runway supports key clinical inflection points through the anticipated Phase III interim readout in 2028.
Negative Updates
Phase III initiation and pivotal development contingent on financing
Although management targets Phase III initiation for givastomig as early as Q4 2026, this timing is explicitly conditional on ongoing planning and securing additional financing, creating execution risk and timing uncertainty.
Read all updates
Q2-2026 Updates
Positive
Negative
Strong liquidity and debt-free balance sheet
As of June 30, 2026, NovaBridge reported approximately $216 million in cash and investments (about $191 million in cash and cash equivalents and $25 million in equity investments at fair value) and a debt-free balance sheet, with management stating this runway supports key clinical inflection points through the anticipated Phase III interim readout in 2028.
Read all positive updates
Company Guidance
The company provided timeline and financing guidance centered on advancing givastomig and VIS-101: as of June 30, 2026 NovaBridge had ~$216M in cash and investments (~$191M cash & cash equivalents, ~$25M equity) on a debt-free balance sheet, which management expects to fund near-term catalysts including updated Phase Ib dose‑expansion data at ESMO (October 2026), completion of enrollment in the randomized Phase II first‑line gastroesophageal adenocarcinoma combination study, and the potential initiation of a Phase III registrational study as early as Q4 2026 (subject to planning/financing), with runway extending through the anticipated Phase III interim data readout in 2028; givastomig received FDA Fast Track in June 2026 and FDA Type B feedback indicating potential eligibility for accelerated approval in first‑line HER2‑negative, CLDN18.2‑positive, PD‑L1‑positive gastroesophageal cancer (Phase Ib combo data at 8 mg/kg showed a 75% ORR, tumor reduction in 51/52 evaluable patients and a preliminary median PFS of 16.9 months), while VIS‑101 (via majority‑owned Visara) reported positive Phase IIa topline results earlier in 2026 and is preparing to initiate a Phase IIb in H2 2026 with the goal of advancing to global Phase III.NovaBridge Biosciences Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
28
Negative
| Breakdown | Mar 2026 | Mar 2025 | Dec 2023 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 4.49M | -10.70M | 88.03M |
| Gross Profit | 0.00 | 0.00 | 4.49M | -10.70M | 41.59M |
| EBITDA | -13.35M | -373.45M | -344.25M | -356.38M | -2.06B |
| Net Income | -6.61M | -162.26M | -1.47B | -967.52M | -2.33B |
Balance Sheet | |||||
| Total Assets | 37.24M | 1.55B | 368.92M | 4.07B | 878.74M |
| Cash, Cash Equivalents and Short-Term Investments | 30.14M | 1.27B | 311.73M | 3.45B | 670.96M |
| Total Debt | 438.46K | 28.33M | 3.89M | 38.29M | 17.64M |
| Total Liabilities | 4.23M | 84.08M | 126.34M | 1.07B | 163.42M |
| Stockholders Equity | 33.02M | 1.47B | 242.58M | 3.01B | 715.33M |
Cash Flow | |||||
| Free Cash Flow | -20.60M | -384.77M | -73.02M | -1.15B | -1.00B |
| Operating Cash Flow | -20.60M | -384.42M | -72.85M | -1.10B | -973.09M |
| Investing Cash Flow | 104.97M | -992.42M | -107.63M | 458.38M | -727.21M |
| Financing Cash Flow | 57.73M | -2.44M | -8.25M | 42.36M | 593.92M |
NovaBridge Biosciences Technical Analysis
1.87
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NBP, the sentiment is undefined. The current price of 1.87 is equal to the 20-day moving average (MA) of ―, equal to the 50-day MA of ―, and equal to the 200-day MA of ―, indicating a neutral trend. The MACD of ― indicates undefined momentum. The RSI at ― is undefined, neither overbought nor oversold. The STOCH value of ― is undefined, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a undefined sentiment for NBP.
NovaBridge Biosciences Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
NovaBridge Biosciences Corporate Events
NovaBridge Biosciences Showcases Global Translation Strategy and Givastomig Accelerated Approval Path in August Investor Deck
Aug 20, 2026
On August 20, 2026, NovaBridge Biosciences released an investor presentation outlining its strategy and operational model for turning promising therapies into commercial and clinical value. The presentation framed the firm as an enabler of global ...
NovaBridge Biosciences Deepens Pipeline Investment as Givastomig and VIS-101 Advance in First-Half 2026
Aug 20, 2026
On August 20, 2026, NovaBridge Biosciences reported unaudited financial results for the six months ended June 30, 2026, alongside a detailed business update, highlighting intensified investment in its oncology and ophthalmology pipeline. The compa...
NovaBridge Biosciences Sets September 8, 2026 AGM in Shanghai and Highlights 2025 Annual Filing
Jul 24, 2026
NovaBridge Biosciences said on July 24, 2026 that it will hold its annual general meeting of shareholders on September 8, 2026 at its Shanghai office, with holders of ordinary shares and American depositary shares of record as of July 27, 2026 ent...
NovaBridge Biosciences Launches 2026 Omnibus Share Incentive Plan
Jul 17, 2026
On July 13, 2026, NovaBridge Biosciences’ board adopted a new 2026 Omnibus Share Incentive Plan that replaces prior equity compensation schemes and consolidates all new awards under a single framework. The plan initially authorizes issuance ...
NovaBridge Biosciences Names New CEO Amid Broad Board and Executive Shake-Up
Jun 29, 2026
On June 29, 2026, NovaBridge Biosciences announced that Srishti Gupta, MD MPP will become chief executive officer and join the board on July 1, 2026, succeeding outgoing CEO Xi-Yong (Sean) Fu, who resigned effective June 30 and will remain an advi...
NovaBridge Biosciences Replaces PwC With Deloitte as Independent Auditor
Jun 16, 2026
On June 16, 2026, NovaBridge Biosciences’ audit committee dismissed PricewaterhouseCoopers as its independent registered public accounting firm and simultaneously appointed Deloitte Touche Tohmatsu Certified Public Accountants as auditor for...
NovaBridge Wins FDA Fast Track for Givastomig in First-Line Gastric Cancer
Jun 16, 2026
On June 16, 2026, NovaBridge Biosciences announced that the U.S. Food and Drug Administration granted Fast Track Designation to its bispecific antibody givastomig, in combination with nivolumab and chemotherapy, for first-line treatment of HER2-ne...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.